WuXi Biologics has strengthened its ESG credentials with a globally recognised milestone. The company announced it has achieved ISO 20400 Sustainable Procurement certification, underscoring its commitment to responsible sourcing, transparency, and resilient supply chains.
ISO 20400 is an international standard that embeds sustainability into procurement decisions. It focuses on:
For a global CRDMO, this signals maturity beyond compliance.
WuXi Biologics has integrated sustainability across the full supplier lifecycle. This includes:
The approach ensures suppliers meet quality, compliance, and sustainability expectations consistently.
The company has aligned its climate strategy with Science Based Targets initiative (SBTi) goals.
Beyond internal targets, WuXi Biologics actively engages suppliers to:
This expands climate impact beyond company boundaries.
Dr Chris Chen, CEO and Chair of the ESG Committee, highlighted the strategic intent.
He emphasized that robust supply chain management is critical to delivering high-quality solutions while enabling sustainable growth across the pharmaceutical value chain.
ISO 20400 adds to a long list of ESG accolades.
WuXi Biologics has received:
The company is also part of FTSE4Good, Hang Seng ESG 50, and rated Prime by ISS ESG.
As a UN Global Compact participant, WuXi Biologics positions sustainability as a growth enabler, not a constraint.
With over 12,000 employees across five countries and 864 active client projects, including 24 commercial programs, responsible procurement is now core infrastructure.
ISO 20400 certification reinforces WuXi Biologics’ status as a sustainability leader among global CRDMOs. It signals to partners that supply chain responsibility, resilience, and ESG performance are non-negotiable.